Caitong International Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Caitong International Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.1K	Buy	608 +577	+1,861%	+$17K	﹤0.01%	968
2026 Q1	$715	Sell	31 -776	-96%	-$17.5K	﹤0.01%	1537
2025 Q4	$16.2K	Buy	+807	New	+$16.8K	﹤0.01%	1037
2025 Q2	–	Sell	-383	Closed	-$7.08K	–	2565
2025 Q1	$7.08K	Buy	383 +370	+2,846%	+$9.05K	0.01%	941
2024 Q4	$346	Buy	+13	New	+$373	﹤0.01%	1517

Other funds holding AVBP

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Caitong International Asset Management's AVBP Position: Q2 2026 in Review

Caitong International Asset Management increased its ArriVent BioPharma (AVBP) stake by 1,861% in Q2 2026, buying an estimated $17K and bringing the position to 608 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #968.

Caitong International Asset Management first reported a position in AVBP in Q4 2024 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

Caitong International Asset Management held 608 shares of ArriVent BioPharma worth $21.1K as of Q2 2026.
Caitong International Asset Management bought 577 ArriVent BioPharma shares in Q2 2026, an estimated $17K.
ArriVent BioPharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #968 holding.
Caitong International Asset Management first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 5 quarters since.
157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.